Prophylactic trimethoprim‐sulfamethoxazole in anti‐neutrophil cytoplasmic autoantibody‐associated vasculitis: comment on the article by Kim et al

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Arthritis & Rheumatology

• Publication date

  2025-06-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/art.43296PMID 40534182
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Time‐Dependent Effect of Prophylactic Trimethoprim‐Sulfamethoxazole on the Incidence of Serious Infections in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Target Trial Emulation Study

  2025cited by this paper
• Recurrence Risk in Pediatric Noninfectious Uveitis During Adalimumab Tapering: An International Multicenter Retrospective Study

  2025influential reference
• EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update

  2023cited by this paper
• Target Trial Emulation to Improve Causal Inference from Observational Data: What, Why, and How?

  2023cited by this paper
• 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

  2021cited by this paper
• Protective effect of different doses of trimethoprim-sulfamethoxazole prophylaxis for early severe infections among patients with antineutrophil cytoplasmic autoantibody-associated vasculitis.

  2021cited by this paper
• 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

  2021cited by this paper
• CanVasc Consensus Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitis: 2020 Update

  2020cited by this paper
• A Dutch consensus statement on the diagnosis and treatment of ANCA-associated vasculitis.

  2019cited by this paper
• Trimethoprim–sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis

  2018cited by this paper
• Trimethoprim-sulfamethoxazole and antineutrophil cytoplasmic antibodies-associated vasculitis.

  2018cited by this paper
• Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group.

  1996cited by this paper

• Trimethoprim/Sulfamethoxazole in Clinical Trials for Granulomatosis With Polyangiitis

  2025cites this paper
• Comment on: Time-Dependent Effect of Prophylactic Trimethoprim-Sulfamethoxazole on the Incidence of Serious Infections in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Target Trial Emulation Study.

  2025cites this paper